Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
112,95 €
1,44 %
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at TD Cowen from $175.00 to $200.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $160.00 to $180.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $183.00 to $188.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at HC Wainwright from $168.00 to $198.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at Truist Financial Corporation from $172.00 to $169.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $179.00 to $177.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by analysts at UBS Group AG from $188.00 to $178.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
Barclays_PLC in Vertex Pharmaceuticals Inc. diskutieren